Chemical compounds

Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

Retrieved on: 
Wednesday, July 21, 2021
Chemical compounds, Organic compounds, Heterocyclic compounds, Orphan drugs, Lactams, Nucleosides, Triazines, Antineoplastic drugs, Azacitidine, Venetoclax, H. Lee Moffitt Cancer Center & Research Institute, 7+3

In addition, the post- transplant regimen of eprenetapopt and azacitidine was well tolerated among patients in the clinical trial.

Key Points: 
  • In addition, the post- transplant regimen of eprenetapopt and azacitidine was well tolerated among patients in the clinical trial.
  • The post-transplant RFS and OS data with eprenetapopt and azacitidine maintenance therapy in these very difficult-to-treat TP53 mutant MDS and AML patients are incredibly exciting, said trial principal investigator Asmita Mishra, M.D., of the H. Lee Moffitt Cancer Center and Research Institute.
  • Post-transplant maintenance therapy with eprenetapopt and azacitidine could, if approved, represent a new treatment paradigm that meaningfully improves outcomes for these patients with limited treatment options.
  • A Phase 1/2 clinical trial of eprenetapopt with venetoclax and azacitidine for the frontline treatment of TP53 mutant AML met the primary efficacy endpoint of complete remission.

The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Clinical trials, Psychiatry, Organic compounds, Chemical compounds, Pimavanserin, Piperidines, Ureas, Aging-associated diseases, Psychosis, Dementia, Clive Ballard, Acadia Pharmaceuticals

Second, in the 26-week double-blind period, patients on pimavanserin had a nearly three-fold reduction of risk of psychosis relapse compared to patients on placebo.

Key Points: 
  • Second, in the 26-week double-blind period, patients on pimavanserin had a nearly three-fold reduction of risk of psychosis relapse compared to patients on placebo.
  • We are very pleased that the New England Journal of Medicine has chosen to publish the important results of this study.
  • HARMONY was a Phase 3 study designed to evaluate the efficacy and safety of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis.
  • The HARMONY study included a 12-week, open-label stabilization period during which patients with dementia-related psychosis began treatment with pimavanserin 34 mg once daily.

Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS)

Retrieved on: 
Wednesday, July 21, 2021
Chemical compounds, Branches of biology, Health, Antineoplastic drugs, Oncology, Syndromes, Tumor lysis syndrome, Venetoclax, Bcl-2, Cancer

NORTH CHICAGO, Ill., July 21, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax (VENCLEXTA®) in combination with azacitidine for the potential treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes (MDS) based on revised International Prognostic Scoring System (IPSS-R). A BTD is intended to expedite the development and review of medications to treat a serious medical condition and is granted when preliminary clinical evidence indicates the investigational therapy may demonstrate substantial improvement over existing therapies.1 This marks the sixth BTD granted to venetoclax.

Key Points: 
  • "This Breakthrough Therapy Designation underscores the need for more treatment options for these patients and the utility of venetoclax to potentially treat different forms of blood cancer."
  • Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood cancers.
  • VENCLEXTA can cause serious side effects, including:
    Tumor lysis syndrome (TLS).TLS is caused by the fast breakdown of cancer cells.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.

VCSEL Market with COVID-19 Impact Analysis by Type, Material, Wavelength, Application, Data Rate, Industry and Region - Global Forecast to 2026

Retrieved on: 
Tuesday, July 20, 2021
Chemistry, Physical sciences, Chemical compounds, Optoelectronics, Vertical-cavity surface-emitting laser, Phosphides, Solar cells, Indium phosphide, Gallium arsenide, Compound annual growth rate, Forecast period

DUBLIN, July 20, 2021 /PRNewswire/ -- The "VCSEL Market with COVID-19 Impact Analysis by Type, Material (GaAs, InP), Wavelength, Application (Sensing, Data Communication, Industrial Heating & Printing, Emerging), Data Rate, Industry, and Region - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 20, 2021 /PRNewswire/ -- The "VCSEL Market with COVID-19 Impact Analysis by Type, Material (GaAs, InP), Wavelength, Application (Sensing, Data Communication, Industrial Heating & Printing, Emerging), Data Rate, Industry, and Region - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • With the entire VCSEL ecosystem is gaining market traction, it is expected to offer growth opportunities during the forecast period.
  • The multimode VCSEL segment is projected to register a higher CAGR during the forecast period.
  • The high adoption of GaAs-based VCSELs in the production of smartphones and consumer devices is the primary growth driver in the market.

Global Losartan Market (2020 to 2026) - by Source, Form, Strength, Distribution Channel, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, Pharmaceutical, Chemical compounds, Aromatic compounds, Angiotensin II receptor antagonists, Chloroarenes, Imidazoles, Losartan, Tetrazoles, Angiotensin II receptor blocker, Marketplace, Financial market

The Global Losartan Market is segmented based on source, form, strength, distribution channel, application, end-user, company and region.

Key Points: 
  • The Global Losartan Market is segmented based on source, form, strength, distribution channel, application, end-user, company and region.
  • To estimate and forecast the market size of the Global Losartan Market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast the Global Losartan Market based on source, form, strength, distribution channel, application, end-user, company and regional distribution.
  • To identify key sustainable strategies adopted by market players in the Global Losartan Market.

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Retrieved on: 
Tuesday, July 20, 2021
Organic compounds, Chemical compounds, Quinazolines, Tyrosine kinase receptors, Amines, Astellas Pharma, Erlotinib, Ethers, Epidermal growth factor receptor, Chemistry

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.

Key Points: 
  • NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.
  • Both product candidates are exclusively licensed forU.S.commercialization withGalderma Holding SA.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

Dystrophin (DMD) Drugs In Development, 2021 Research Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, Pharmaceutical, Muscular dystrophy, Branches of biology, Dystrophin, DMD, Chemical compounds, Organic compounds, Ezutromid, Drisapersen

The "Dystrophin (DMD) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dystrophin (DMD) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Dystrophin (DMD) - Dystrophin is a cytoplasmic protein.
  • The report 'Dystrophin - Drugs In Development, 2021' outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
  • It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects.

Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids

Retrieved on: 
Tuesday, July 20, 2021
Drugs, Chemical compounds, Chemistry, Combination drugs, Estrogens, Estranes, Prolactin releasers, GnRH antagonists, Relugolix/estradiol/norethisterone acetate, Uterine fibroid, Relugolix, Estradiol

With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.

Key Points: 
  • With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.
  • Todays approval of RYEQO, the first and only once-daily long-term treatment for women with uterine fibroids in Europe, marks a major milestone in expanding non-invasive treatment options for this common and potentially debilitating disease, said David Marek, Chief Executive Officer of Myovant Sciences, Inc.
  • Through our partnership with Gedeon Richter, we look forward to supporting even more women suffering from uterine fibroids.
  • RYEQO (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis

Retrieved on: 
Monday, July 19, 2021
Chemical compounds, Organic compounds, Amides, Ethers, Morpholines, Pyridines, Tirbanibulin, Chemistry, Actinic keratosis, Almirall, AK

This approval by the European Commission marks another significant milestone for Klisyri, shortly following the marketing approval and launch of Klisyri in the U.S., said Dr. Johnson Lau, Chief Executive Officer of Athenex.

Key Points: 
  • This approval by the European Commission marks another significant milestone for Klisyri, shortly following the marketing approval and launch of Klisyri in the U.S., said Dr. Johnson Lau, Chief Executive Officer of Athenex.
  • In December 2020, Athenex received approval from the U.S. Food and Drug Administration (FDA) for the commercialization of Klisyri (tirbanibulin) in the U.S. for the topical treatment of AK of the face or scalp.
  • Our partner Almirall led the U.S. launch of Klisyri in February and is leading the launch of Klisyri in Europe.
  • Klisyri (tirbanibulin) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) of the face or scalp.

Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis

Retrieved on: 
Monday, July 19, 2021
Chemistry, Chemical compounds, Physical sciences, Amides, Ethers, Morpholines, Pyridines, Tirbanibulin, Actinic keratosis, Almirall, Keratosis, AK

BARCELONA, Spain, July 19, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the European Commission (EC) has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp in adults.

Key Points: 
  • BARCELONA, Spain, July 19, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the European Commission (EC) has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp in adults.
  • "The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek for new treatments that could offer them a better tolerability and short treatment duration.
  • In addition, Almirall has submitted Klisyri for a marketing authorisation in Switzerland in Q4 2020 and the dossier is currently under review by Swissmedic.
  • [4]Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective.